BiondVax to develop nanosized COVID-19 antibody therapy, shares gain
22/12/2021 13:44
** U.S.-listed shares of Israel-based pharmaceutical firm
BVXV.O jump 48% to a five-week high of $2.20 premarket
** Co agrees for development and commercialization of
innovative nanosized COVID-19 antibody therapy with
Germany-based research firms
** Co to develop therapies with Max Planck Society (MPG),
the parent organization of the Max Planck Institute of
Biophysical Chemistry, and the University Medical Center
Göttingen, both in Germany
** Agreements are part of broader collaboration, expected to
be signed in January 2022, covering development and
commercialization of NanoAbs for several other disease
indications - Co
** Lead NanoAb candidates for COVID-19 program exhibit a
strong competitive edge over existing COVID-19 therapies
** NanoAbs are novel nanosized antibodies also known as
VHH-antibodies or nanobodies
** Stock has lost ~47% YTD
(Reporting by Shashank Nayar in Bengaluru)
((Shashank.Nayar@thomsonreuters.com; within U.S. +1 646 223
8780; outside U.S. +91 80 6182 2256;))